Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A pair for pain therapies
November 2015
SHARING OPTIONS:

STAMFORD, Conn. & SAN DIEGO—Purdue Pharma L.P. and AnaBios Corp. recently shared news of their intent to create a joint venture focused on speeding the development of Purdue Pharma’s Nav1.7 sodium ion channel compounds for the treatment of chronic pain. This joint effort would combine Purdue Pharma’s intellectual property and lead compounds with AnaBios’ Phase-X technology. No additional details were disclosed.
 
“We are very excited to have the opportunity to employ AnaBios’ Phase-X technology to optimize the selection of clinical candidates from the advanced leads that Purdue Pharma has generated,” said Dr. Andre Ghetti, CEO of AnaBios. “Employing human sensory neurons to match the selectivity and properties of sodium channel blockers with specific pain indications, we will maximize the potential success of clinical development of much-needed new pain therapeutics.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.